Research programme: heart failure therapeutic - Bio-Medisinsk Innovasjon/GlaxoSmithKline
Latest Information Update: 01 Aug 2016
At a glance
- Originator Bio-Medisinsk Innovasjon; GlaxoSmithKline
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Heart failure